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The eye care sector is well positioned to contribute to the advancement of universal health coverage within countries. 
Given the large unmet need for care associated with cataract and refractive error, coupled with the fact that highly 
cost-effective interventions exist, we propose that effective cataract surgery coverage (eCSC) and effective refractive 
error coverage (eREC) serve as ideal indicators to track progress in the uptake and quality of eye care services at the 
global level, and to monitor progress towards universal health coverage in general. Global targets for 2030 for these 
two indicators were endorsed by WHO Member States at the 74th World Health Assembly in May, 2021. To develop 
consensus on the data requirements and methods of calculating eCSC and eREC, WHO convened a series of expert 
consultations to make recommendations for standardising the definitions and measurement approaches for eCSC 
and eREC and to identify areas in which future work is required.
Introduction
Achieving universal health coverage (UHC)—ensuring 
all people can receive the high-quality health services 
they need, without experiencing financial hardship—is a 
WHO strategic priority.1 The eye care sector is well 
positioned to contribute to the advancement of UHC 
within countries given that there is a large unmet need 
for eye health services (around 1 billion people have a 
vision impairment that could have been prevented or is 
yet to be addressed),2 and given that effective interventions 
are available to address the needs associated with eye 
conditions and vision impairment. Some of these 
interventions are among the most feasible and cost-
effective of all health-care interventions to implement.3,4
To understand how actions and investments in the 
field of eye care are delivering on the goal of improving 
eye health outcomes and contributing to the advance-
ment of UHC, it is essential to identify tracer indicators 
that fulfil several important criteria. First, the selected 
indicators must serve as a reasonable proxy for the 
overall status of eye care services and consider different 
segments of the population (eg, across the life course). 
Second, the indicators need to be based on cost-effective 
interventions, with clearly outlined steps for improving 
their coverage. Third, variation in the indicator should 
primarily reflect health system factors rather than factors 
outside the control of the health system. Lastly, there are 
practical considerations, including the need for the 
indicators to have accompanying baseline information 
and to be feasibly monitored in a large number of 
countries across all income levels.
Uncorrected refractive error and unoperated cataract 
are the leading causes of vision impairment globally.5 
More than 800 million people have distance or near vision 
impairment that could be addressed with an appropriate 
pair of spectacles,2 and an estimated 100 million people 
have moderate-to-severe distance vision impairment or 
blindness that could be corrected through access to 
cataract surgery.5 These figures are expected to increase 
because presbyopia and cataract development are part of 
the ageing process, while growing evidence suggests that 
projected increases in myopia in the younger population 
will be driven largely by lifestyle-related risk factors.2
For these reasons, we propose that the population-
based indicators of effective cataract surgery coverage 
(eCSC) and effective refractive error coverage (eREC) 
serve as ideal proxy indicators to not only track changes 
in the uptake and quality of eye care services6 at the global 
level, but also contribute to monitoring progress towards 
UHC in general.7 eREC involves ongoing access to, 
and uptake of, services (as needs change) through what 
is often a range of provider options, whereas eCSC 
involves a shorter-term, surgical intervention. Thus, the 
two indicators complement each other in how they reflect 
overall performance of health systems in providing 
access to high-quality eye care services.
Importantly, these indicators not only capture the 
extent of coverage, but also the concept of effective 
coverage, to ensure that people who need health services 
receive them with sufficient quality to produce the 
expected health outcome.8
Member States recognise the importance of 
eCSC and eREC and request global 2030 targets
In November, 2020, the resolution titled Integrated people-
centered eye care, including preventable vision impairment 
and blindness was adopted by Member States at the 
73rd World Health Assembly.9 This resolution requested 
that WHO, in consultation with Member States, 
prepare recommendations on feasible global targets for 
2030 focusing on eCSC and eREC. To this end, WHO 
undertook a consultative process10 with Member States, 
and experts from the field, to develop global targets for 
eCSC and eREC that were endorsed by the 74th World 
Health Assembly in May, 2021.
The ability to collect a representative volume of data 
(both within and across countries) from population-
based surveys, periodically and in a standardised 
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keels@who.int manner, will be crucial to ensure robust reporting and 
monitoring of progress towards achieving the global 
targets for eCSC and eREC. In July, 2020, consultations 
were held with a WHO Expert Working Group, 
composed of individuals in the field of eye care in the 
areas of epidemiology and public health, to work with 
WHO to review the methods of calculating eCSC and 
eREC. The key proposals from these consultations were 
the subject of a broader web-based consultation (Oct 13 
to Nov 3, 2020), which was open to Member States, 
other intergovernmental organisations, and non-State 
actors in the field of eye care. The outcomes of this 
series of WHO technical consultations, including the 
definitions, recommended calculation methods, and 
key considerations for both eCSC and eREC, are 
presented in this Health Policy paper.
Effective cataract surgery coverage
Definition and calculation method
eCSC is defined as the proportion of adults aged 50 years 
and older who are in need of cataract surgery, who have 
received this surgery, and have a resultant good-quality 
distance visual acuity outcome. The recommended 
method of calculation of eCSC is detailed in panel 1.
Considerations
To date, there has been considerable inconsistency in the 
visual acuity thresholds applied for both the need of 
surgery and what constitutes a good outcome following 
surgery.11,12 In recognition that the aspiration of UHC is 
universal and that everyone should receive the health 
services they need, irrespective of their income level 
or any other factors, we provide recommendations to 
promote consistent reporting on the visual acuity 
thresholds applied in the calculation of eCSC. 
The recommended threshold for defining a good 
outcome following cataract surgery is a presenting visual 
acuity (PVA—ie, unaided vision; or, if spectacles or 
contact lenses are worn to the assessment, visual acuity 
is measured with the person wearing them) of 6/12 or 
better. At an informal consultation held in Geneva in 
1998, a good outcome was defined as a PVA of 6/18 or 
better.13 The change in the upper visual acuity threshold 
from 6/18 to 6/12 recommended herein is in recog-
nition of a growing body of evidence that mild vision 
impairment (ie, <6/12–6/18) has a notable impact on the 
everyday functioning of individuals.14,15 Furthermore, 
given the advances in surgical techniques for cataract, 
coupled with improvements in intraocular lens design 
over the past two decades, it is now reasonable to expect 
higher-quality outcomes following cataract surgery.16–18 
The use of PVA is recommended when reporting on the 
visual outcome because it reflects an individual’s visual 
acuity in everyday life following surgery, and it also 
allows for deficiencies in intraocular lens availability (eg, 
access to toric intraocular lenses) and equipment for 
intraocular lens power calculation (ie, keratometry and 
biometry), which can be common in low-resource 
settings.
For the global reporting framework, the estimated 
population in need of cataract surgery will be defined as 
individuals with best-corrected visual acuity (BCVA) of 
less than 6/12 with cataract as the main cause of vision 
impairment. This threshold was selected because it 
is consistent with the International Classification of 
Diseases (11th revision) definition of vision impairment, 
indicating that visual acuity of less than 6/12 requires an 
intervention which, in this case, is cataract surgery. 
Adopting this better visual acuity threshold, rather than, 
for example, a threshold of less than 6/18, broadens the 
range of what we define as a vision-impairing cataract 
that requires surgery within the population. This might 
result in a shift in practice to recommend cataract surgery 
earlier, an outcome that could lead to a reduced frequency 
of surgical complications, improved visual outcomes, 
and the earlier recovery of useful vision.19
The indication for cataract surgery, however, is 
contingent upon a range of factors including the 
patient’s felt need for surgery. Accordingly, the visual 
requirements of different groups of the population 
might be very different and, therefore, a BCVA of less 
than 6/12 might not reflect the felt need for cataract 
surgery for all segments of the population. In addition, 
thresholds for cataract surgery depend on the health 
system context and eligibility criteria for surgery in each 
country—ie, countries with less comprehensive and 
capable health systems often use lower thresholds for 
defining the indication for surgery. To give a degree of 
Panel 1: Recommended calculation method for effective 
cataract surgery coverage
• a=individuals with unilateral operated cataract attaining 
PVA ≥6/12 in the operated eye, who have BCVA <6/12 with 
cataract as the main cause of vision impairment or 
blindness in the other eye
• b=individuals with bilateral operated cataract attaining 
PVA ≥6/12 in at least one eye
• c=individuals with unilateral operated cataract (regardless 
of visual acuity in the operated eye), who have BCVA <6/12 
with cataract as the main cause of vision impairment or 
blindness in the other eye
• d=individuals with bilateral operated cataract, regardless of 
visual acuity
• e=individuals with BCVA <6/12 with cataract as the main 
cause of vision impairment or blindness in both eyes
All visual acuities are measured for distance. PVA=presenting visual acuity; if spectacles 
or contact lenses are worn to the assessment, visual acuity is measured with the person 
wearing them. BCVA=best-corrected visual acuity; visual acuity is assessed either by 
pinhole or refraction.
a + b
c + d + e
× 100( )
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flexibility to health systems under different stages of 
development, countries might elect to additionally 
calculate effective coverage estimates at lower thresholds 
of BCVA (ie, <6/18 and <6/60 with cataract as the 
main cause of vision impairment or blindness). This 
subanalysis will be possible given that existing survey 
methodologies in the field, and any new guidance 
developed by WHO, will, at a minimum, enable 
reporting at the key visual acuity thresholds in line with 
the WHO definitions of vision impairment (ie, 6/12, 
6/18, 6/60, 3/60).
Effective refractive error coverage
Definition and calculation method
eREC is defined as the proportion of people in need of 
refractive error services who have received services (ie, 
spectacles, contact lenses, or refractive surgery) and 
have a resultant good-quality outcome. Given the well 
established impact of near vision impairment on quality 
of life and productivity,20,21 spectacle coverage for both 
distance vision refractive error and near vision 
impairment due to presbyopia will be considered in the 
global monitoring of eREC. Because individuals can 
have both presbyopia and distance vision impairment 
due to refractive error, eREC for distance and near 
vision should be measured and reported separately in 
all relevant population age groups. The recommended 
method of calculation of distance vision eREC is 
outlined in panel 2 and that of near vision eREC in 
panel 3. Flow charts of the visual acuity measurements 
required to calculate distance and near vision eREC are 
depicted in the appendix (pp 1–2).
Considerations
The key distinguishing principle of the proposed method 
of calculation for eREC, when compared with approaches 
adopted previously,22 is the use of uncorrected visual 
acuity (UCVA) to determine the met need of refractive 
error correction (where met need means individuals with 
UCVA <6/12 in the better eye who present with spectacles 
or contact lenses for distance vision and whose PVA is 
≥6/12 in the better eye). Accurate information on the met 
need of refractive error correction is crucial for services 
planning. Previous reports rely on the assumption that 
all people who wear refractive correction for distance 
vision have vision impair ment without their correction 
(where met need means individuals who present with 
spectacles or contact lenses for distance vision and whose 
PVA is ≥6/12 in the better eye). To compare the accuracy 
of the two methods of calculating distance vision eREC, 
direct (ie, within-survey) comparisons were conducted 
within four population-based samples from China 
(Shunyi), Nepal (Kaski), South Africa (Durban) and the 
USA (Los Angeles, CA). This analysis revealed that the 
use of PVA (only) to determine the met need leads to an 
overestimation of the true eREC value (see appendix 
pp 3–4), providing support for the adoption of the 
calculation method described herein.
We recommend that a history of refractive surgery 
is also considered when calculating distance vision 
eREC so as not to underestimate the met need component 
of the calculation method. This is in recognition 
that refractive surgery is highly prevalent in many 
countries,23,24 particularly high-resource settings.25 Future 
work is required to develop and validate questions that 
accurately ascertain a history of refractive surgery among 
survey participants.
Panel 2: Recommended calculation method for distance 
vision effective refractive error coverage
• a=individuals with UCVA <6/12 in the better eye who 
present with spectacles or contact lenses for distance 
vision and whose PVA is ≥6/12 in the better eye (met need)
• b=individuals with a history of refractive surgery whose 
UCVA is ≥6/12 in the better eye (met need)
• c=Individuals with UCVA <6/12 in the better eye who 
present with spectacles or contact lenses for distance 
vision and have PVA <6/12 in the better eye, but who 
improve to ≥6/12 on pinhole or refraction (undermet 
need)
• d=individuals with UCVA <6/12 in the better eye who do 
not have distance vision correction and who improve to 
≥6/12 on pinhole or refraction (unmet need)
UCVA=uncorrected visual acuity; if spectacles or contact lenses are worn to the 
assessment, visual acuity is measured with the person not wearing them.
PVA=presenting visual acuity; if spectacles or contact lenses are worn to the 
assessment, visual acuity is measured with the person wearing them. 
Panel 3: Recommended calculation method for near vision 
effective refractive error coverage
• a=individuals with UCVA <N6 at 40 cm in the better eye 
who present with spectacles for near vision and whose PVA 
is ≥N6 in the better eye (met need)
• b=individuals with distance BCVA ≥6/12* in at least one 
eye who present with spectacles for near vision and whose 
PVA is <N6 in the better eye (undermet need)
• c=individuals with distance BCVA ≥6/12 in at least one eye 
who do not have correction for near vision and whose 
UCVA is <N6 in the better eye (unmet need)
UCVA=uncorrected visual acuity; if spectacles or contact lenses are worn to the assess-
ment, visual acuity is measured with the person not wearing them. PVA=presenting 
visual acuity; if spectacles or contact lenses are worn to the assessment, visual acuity is 
measured with the person wearing them. BCVA=best-corrected visual acuity; visual 
acuity is assessed either by pinhole or refraction. *Only individuals with distance 
BCVA ≥6/12 will be considered in order to exclude those with reduced near vision not 
due to other causes.
a + b
a + b + c + d
× 100( )
a
a + b + c
× 100( )
See Online for appendix
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Discussion
We have described the rationale for the selection of two 
proposed global tracer indicators—eCSC and eREC—to 
monitor the uptake and quality of eye care services at the 
global level, their recommended calculation methods, 
and other key considerations when measuring and 
reporting on these indicators within population-based 
surveys. Global targets for 2030 for these two indicators 
were endorsed by WHO Member States at the 74th World 
Health Assembly in 2021. The essential purpose of these 
indicators and related targets is to drive eye health 
coverage while delivering care of acceptable quality.
It is important to emphasise that eCSC and eREC serve 
as tracer indicators to monitor eye care at a global level, 
but a much more comprehensive range of input, process, 
output, outcome, and impact indicators are required, 
as appropriate, to monitor eye care at the national 
and subnational levels.26 To this end, WHO, through 
consultation with international experts, is in the process 
of developing a comprehensive menu of indicators that 
Member States can select from to facilitate monitoring of 
strategies and actions for eye care provision at the 
national and subnational levels.
Adopting the recommended high thresholds to 
define the need for cataract surgery has the potential 
for unintended consequences in reaching the most 
vulnerable, particularly in countries with less advanced 
health systems. That is, in the pursuit of improving 
eCSC based on a higher visual acuity threshold, countries 
might favour providing access to those population groups 
that are more easily accessed and treated or to the most 
promising and uncomplicated cases (ie, without ocular 
comorbidity), with a result of the equity gap remaining or 
widening in traditionally disadvantaged and harder-to-
reach populations (eg, people of low socioeconomic 
status, rural dwellers, women, or older people). Due to 
the importance of safeguarding against the exclusion of 
these populations, data will need to be collected, analysed, 
and reported in a stratified manner when monitoring 
both eCSC and eREC. To this end, it is recommended 
that eCSC and eREC estimates should be disaggregated 
by age, gender, socioeconomic status, geography, and any 
other relevant sociodemographic stratifiers.
There are some potential limitations of the proposed 
indicator calculation methods that should be considered. 
First, because it is not possible to ascertain pre-cataract 
surgery visual acuity, the eCSC calculation method 
assumes that all participants who have undergone 
surgery had a presurgical BCVA of less than 6/12. 
Although this is a reasonable assumption for lower-
resource settings, it might result in an overestimation of 
coverage in higher-resource settings, where surgery is 
often done at higher visual acuity thresholds. Second, the 
use of pinhole visual acuity to establish an individual’s 
BCVA is by no means equivalent to a refraction. Despite 
this, due to feasibility considerations, most existing rapid 
assessment survey methodologies use pinhole visual 
acuity as a proxy for BCVA. Third, when assigning the 
main cause of vision impairment in the survey context, 
there might be an intrinsic overestimation of cataract 
because this process tends to favour those conditions 
that are addressable and easier to identify. This bias 
could lead to an overestimation of the need for cataract 
surgery and an underestimation of the effectiveness 
of cataract surgery, because a poor cataract surgery 
outcome can be present due to coexisting disease. Before 
the widespread application of the proposed indi cator 
calculation methods, additional sensitivity analysis will 
be done on the aforementioned variables by use of 
historical data and, additionally, the reliability of these 
indicators will be piloted and validated in prospective 
population-based surveys.
Given that the data source for these outcome indicators 
will be validated population-based surveys, we expect that 
the estimates generated will be reliable and accurate. 
However, there are some potential barriers to the robust 
monitoring of progress towards achieving the indicator 
targets, including the demand for additional resources to 
collect data, particularly in low-resource settings. To this 
end, in the context of one of WHO’s core functions—
monitoring and assessing health trends—WHO will 
support the conduct of country-level data collection on 
the selected eye care indicators in low-resource and 
intermediate-resource settings. In addition, efforts are 
underway to further standardise survey instruments and 
methods of implementation, and to promote more 
widespread data collection across all relevant target 
populations in the future. Firstly, at the request of 
Member States,27 WHO, together with relevant experts, is 
developing a feasible and financially viable survey 
methodology to facilitate the collection of data on the two 
indicators. Secondly, work is already underway to 
incorporate a standardised vision module within existing 
WHO health surveys, including the STEPwise approach 
to surveillance (STEPS).28 
If both quality and quantity of data can be ensured, 
eCSC and eREC can be considered as candidates for 
effective coverage indicators within WHO’s framework 
for monitoring progress towards UHC, and within 
WHO’s next General Programme of Work. Such an 
outcome would be of notable benefit to the people in 
need of eye care, potentially increasing government 
investments to offer eye care services within the broader 
context of UHC.
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